AstraZeneca's COVID vaccine Vaxzevria gets full approval in EU
Ulet Ifansasti/Getty Images News


AstraZeneca (NASDAQ:AZN) said its COVID-19 vaccine Vaxzevria was granted full marketing authorization (MA) in the EU.
Vaxzevria (ChAdOx1-S [Recombinant] formerly AZD1222), developed with the Oxford University, was originally granted a conditional MA. The European Medicines Agency (EMA) has now granted a full MA based on sufficient evidence of safety and efficacy of Vaxzevria, the British drugmaker said in a press release on Tuesday.

The MA covers the use of Vaxzevria as a primary vaccination series, and as both a heterologous (with an approved mRNA COVID-19 vaccine) or homologous (all the same vaccine) third dose booster, the company added.
AstraZeneca and its global partners have released over 3B doses of Vaxzevria to more than 180 countries, and about two-thirds of these doses have been delivered to low- and lower-middle-income countries, according to the company.
During Q2, Vaxzevria sales had declined -48% Y/Y to $451M.